We Did The Math TMSL Can Go To $38

Written by Emily J. Thompson, Senior Investment Analyst

CNTA+0.65%

TMSL-0.39%

KYMR-2.62%

Source: NASDAQ.COM

Updated: Jun 10 2025

0mins

Source: NASDAQ.COM

ETF Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $37.77 per unit, indicating a potential upside of 17.08% from its current trading price of $32.27.
Stock Performance Insights: Notable underlying holdings such as Centessa Pharmaceuticals, Kymera Therapeutics, and Primoris Services show significant upside potential based on analyst target prices, raising questions about the validity and optimism of these targets in light of recent market developments.

CNTA

$24.81+Infinity%1D

Analyst Views on CNTA

Wall Street analysts forecast CNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTA is 38.75 USD with a low forecast of 27.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Analyst Rating

13 Buy

0 Hold

0 Sell

Strong Buy

Current: 24.650

Low

27.00

Averages

38.75

High

62.00

Current: 24.650

Low

27.00

Averages

38.75

High

62.00

Truist

Danielle Brill

Buy

maintain

$30 -> $33

2026-01-08

Reason

Truist

Danielle Brill

Price Target

$30 -> $33

AI Analysis

2026-01-08

maintain

Buy

Reason

Truist analyst Danielle Brill raised the firm's price target on Centessa to $33 from $30 and keeps a Buy rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.

Needham

Buy

maintain

$35 -> $38

2026-01-05

Reason

Needham

Price Target

$35 -> $38

2026-01-05

maintain

Buy

Reason

Needham raised the firm's price target on Centessa to $38 from $35 and keeps a Buy rating on the shares. The stock's momentum is likely to continue in 2026 due to additional data from the ongoing dose escalation cohorts in ORX-750's ongoing Phase 2a study, the analyst tells investors in a research note. Needham believes Centessa is likely one of the most attractive biotechnology acquisition targets in 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CNTA

Unlock Now

Oppenheimer

Outperform

upgrade

$40 -> $62

2025-12-10

Reason

Oppenheimer

Price Target

$40 -> $62

2025-12-10

upgrade

Outperform

Reason

Oppenheimer assumed coverage of Centessa with an Outperform rating with a price target of $62, up from $40. Centessa is a top pick for the firm. Oppenheimer notes that the company's pipeline includes best-in-class orexin agonists, with an expected commercialization in the first half of 2028 that can significantly expand the size of the current narcolepsy market via higher diagnosis/uptake/compliance/pricing compared to approved drugs. The firm thinks Centessa is significantly undervalued and expects upside potential during data readouts throughout 2026 and beyond.

Stifel

maintain

2025-11-05

Reason

Stifel

Price Target

2025-11-05

maintain

Reason

Stifel expects shares of Alkermes (ALKS) to move higher on the narcolepsy type 1 data reported by Centessa (CNTA). The initial clinical disclosure from Centessa's orexin program does not look superior to Alkermes' ALKS2680, the analyst tells investors in a research note. Stifel says Alkermes shares were pricing in some fear that Centessa could have a much superior profile. The firm believes orexins could be a "significant blockbuster class" with room for many players. It keeps a Buy rating on Alkermes. The stock in morning trading is up 10%, or $2.90, to $33.29.

About CNTA

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.